BioCentury | Oct 3, 2005
Finance

4Q Financial Preview: Hold vs. fold

...a challenge to get it at attractive valuations, according to Paul Nichols, a banker at CS First Boston...
BioCentury | Nov 8, 2004
Finance

Ebb & Flow

...its Tocosol forumulation of paclitaxel. Exit poll Ravi Mehrotra, head of European biotech research at CS First Boston...
BioCentury | Sep 13, 2004
Analyst Picks & Changes

Analyst picks & changes

...Analyst picks & changes Company Bank Analyst Coverage Opinion Acambis (LSE:ACM; ACAM) CS First Boston Andrew Sinclair New...
...BioCentury, Sept. 6). MOGN closed Friday at $28.18, down $1.10 on the week. NicOx (NM:NICOX) CS First Boston...
BioCentury | May 24, 2004
Finance

Restarting the engine

...and Geoff Meacham, who covers small and mid-cap biotech. Elsewhere, Ravi Mehrotra will be joining CS First Boston...
BioCentury | May 3, 2004
Finance

Ebb & Flow

...private placements in the firm's Charlotte, N.C., office. Previously he was a managing director at CS First Boston...
BioCentury | Mar 22, 2004
Finance

Ebb & Flow

...DNA division, is in Phase II trials in multiple tumor types. Underwriters are Goldman Sachs; CS First Boston...
BioCentury | Mar 15, 2004
Finance

Ebb & Flow

...was looking to raise $69-$80.5 million through the sale of 5.75 million shares at $12-$14. CS First Boston...
BioCentury | Mar 9, 2004
Financial News

Peninsula postpones IPO

...at $299 million. The deal was expected to price Tuesday or Wednesday. In addition to CS First Boston...
BioCentury | Feb 17, 2004
Top Story

Ark planning IPO

...U.K.) formalized its plans to IPO on London's main market in a deal underwritten by CS First Boston...
BioCentury | Feb 16, 2004
Finance

Ebb & Flow

...amended the deal to sell 5 million shares at $14-$16. Banks on the deal were CS First Boston...
Items per page:
1 - 10 of 116
BioCentury | Oct 3, 2005
Finance

4Q Financial Preview: Hold vs. fold

...a challenge to get it at attractive valuations, according to Paul Nichols, a banker at CS First Boston...
BioCentury | Nov 8, 2004
Finance

Ebb & Flow

...its Tocosol forumulation of paclitaxel. Exit poll Ravi Mehrotra, head of European biotech research at CS First Boston...
BioCentury | Sep 13, 2004
Analyst Picks & Changes

Analyst picks & changes

...Analyst picks & changes Company Bank Analyst Coverage Opinion Acambis (LSE:ACM; ACAM) CS First Boston Andrew Sinclair New...
...BioCentury, Sept. 6). MOGN closed Friday at $28.18, down $1.10 on the week. NicOx (NM:NICOX) CS First Boston...
BioCentury | May 24, 2004
Finance

Restarting the engine

...and Geoff Meacham, who covers small and mid-cap biotech. Elsewhere, Ravi Mehrotra will be joining CS First Boston...
BioCentury | May 3, 2004
Finance

Ebb & Flow

...private placements in the firm's Charlotte, N.C., office. Previously he was a managing director at CS First Boston...
BioCentury | Mar 22, 2004
Finance

Ebb & Flow

...DNA division, is in Phase II trials in multiple tumor types. Underwriters are Goldman Sachs; CS First Boston...
BioCentury | Mar 15, 2004
Finance

Ebb & Flow

...was looking to raise $69-$80.5 million through the sale of 5.75 million shares at $12-$14. CS First Boston...
BioCentury | Mar 9, 2004
Financial News

Peninsula postpones IPO

...at $299 million. The deal was expected to price Tuesday or Wednesday. In addition to CS First Boston...
BioCentury | Feb 17, 2004
Top Story

Ark planning IPO

...U.K.) formalized its plans to IPO on London's main market in a deal underwritten by CS First Boston...
BioCentury | Feb 16, 2004
Finance

Ebb & Flow

...amended the deal to sell 5 million shares at $14-$16. Banks on the deal were CS First Boston...
Items per page:
1 - 10 of 116